Soto Lopes Marien Siqueira, Trope Beatriz Moritz, Rochedo Rodriguez Maria Paula Rua, Grynszpan Rachel Lima, Cuzzi Tullia, Ramos-E-Silva Marcia
Sector of Dermatology and Post-Graduation Course - HUCFF-UFRJ and School of Medicine, Rio de Janeiro, Brazil.
Sector of Pathology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Case Rep Dermatol. 2013 Nov 7;5(3):326-31. doi: 10.1159/000350930. eCollection 2013.
Golimumab is a human monoclonal antibody, used for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Adverse reactions are increasing with this class of medication (tumor necrosis factor α inhibitors).
The authors present a case of a female patient who presented with psoriasis pustulosa after the use of golimumab for rheumatoid arthritis.
Paradoxically, in this case, golimumab, which is used for psoriasis, induced the pustular form of this disease. We are observing an increasing number of patients who develop collateral effects with tumor necrosis factor α inhibitors, and the understanding of the mechanism of action and how these adverse reactions occur may contribute to avoid these sometimes severe situations.
戈利木单抗是一种人源单克隆抗体，用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎。这类药物（肿瘤坏死因子α抑制剂）的不良反应正在增加。
作者报告了一例女性患者，该患者在使用戈利木单抗治疗类风湿性关节炎后出现了脓疱型银屑病。
矛盾的是，在该病例中，用于治疗银屑病的戈利木单抗诱发了该病的脓疱型。我们观察到越来越多的患者出现肿瘤坏死因子α抑制剂的副作用，了解其作用机制以及这些不良反应如何发生可能有助于避免这些有时很严重的情况。
